Cargando…
Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
Triple-negative breast cancer (TNBC) has a poor prognosis as the therapy has several limitations, most importantly, treatment resistance. In this study we examined the different responses of triple-negative breast cancer line MDA-MB-231 and hormone receptor-positive breast cancer line MCF7 to a comb...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921931/ https://www.ncbi.nlm.nih.gov/pubmed/33669671 http://dx.doi.org/10.3390/ijms22042056 |
_version_ | 1783658571865522176 |
---|---|
author | Andreidesz, Kitti Koszegi, Balazs Kovacs, Dominika Bagone Vantus, Viola Gallyas, Ferenc Kovacs, Krisztina |
author_facet | Andreidesz, Kitti Koszegi, Balazs Kovacs, Dominika Bagone Vantus, Viola Gallyas, Ferenc Kovacs, Krisztina |
author_sort | Andreidesz, Kitti |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) has a poor prognosis as the therapy has several limitations, most importantly, treatment resistance. In this study we examined the different responses of triple-negative breast cancer line MDA-MB-231 and hormone receptor-positive breast cancer line MCF7 to a combined treatment including olaparib, a poly-(ADP ribose) polymerase (PARP) inhibitor, oxaliplatin, a third-generation platinum compound and LY294002, an Akt pathway inhibitor. We applied the drugs in a single, therapeutically relevant concentration individually and in all possible combinations, and we assessed the viability, type of cell death, reactive oxygen species production, cell-cycle phases, colony formation and invasive growth. In agreement with the literature, the MDA-MB-231 cells were more treatment resistant than the MCF7 cells. However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition. Our results suggest that, at therapeutically relevant concentrations, the cytotoxicity of the platinum compound dominated over that of the PARP inhibitor and the PI3K inhibitor, even though a regression-based model could have indicated an overall synergy at lower and/or higher concentrations. |
format | Online Article Text |
id | pubmed-7921931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79219312021-03-03 Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells Andreidesz, Kitti Koszegi, Balazs Kovacs, Dominika Bagone Vantus, Viola Gallyas, Ferenc Kovacs, Krisztina Int J Mol Sci Article Triple-negative breast cancer (TNBC) has a poor prognosis as the therapy has several limitations, most importantly, treatment resistance. In this study we examined the different responses of triple-negative breast cancer line MDA-MB-231 and hormone receptor-positive breast cancer line MCF7 to a combined treatment including olaparib, a poly-(ADP ribose) polymerase (PARP) inhibitor, oxaliplatin, a third-generation platinum compound and LY294002, an Akt pathway inhibitor. We applied the drugs in a single, therapeutically relevant concentration individually and in all possible combinations, and we assessed the viability, type of cell death, reactive oxygen species production, cell-cycle phases, colony formation and invasive growth. In agreement with the literature, the MDA-MB-231 cells were more treatment resistant than the MCF7 cells. However, and in contrast with the findings of others, we detected no synergistic effect between olaparib and oxaliplatin, and we found that the Akt pathway inhibitor augmented the cytostatic properties of the platinum compound and/or prevented the cytoprotective effects of PARP inhibition. Our results suggest that, at therapeutically relevant concentrations, the cytotoxicity of the platinum compound dominated over that of the PARP inhibitor and the PI3K inhibitor, even though a regression-based model could have indicated an overall synergy at lower and/or higher concentrations. MDPI 2021-02-19 /pmc/articles/PMC7921931/ /pubmed/33669671 http://dx.doi.org/10.3390/ijms22042056 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Andreidesz, Kitti Koszegi, Balazs Kovacs, Dominika Bagone Vantus, Viola Gallyas, Ferenc Kovacs, Krisztina Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title_full | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title_fullStr | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title_full_unstemmed | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title_short | Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells |
title_sort | effect of oxaliplatin, olaparib and ly294002 in combination on triple-negative breast cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921931/ https://www.ncbi.nlm.nih.gov/pubmed/33669671 http://dx.doi.org/10.3390/ijms22042056 |
work_keys_str_mv | AT andreideszkitti effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells AT koszegibalazs effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells AT kovacsdominika effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells AT bagonevantusviola effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells AT gallyasferenc effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells AT kovacskrisztina effectofoxaliplatinolaparibandly294002incombinationontriplenegativebreastcancercells |